Bio-Path Holdings, Inc.
(NASDAQ : BPTH)

( )
BPTH After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen Inc.
-0.24%343.281.2%$589.37m
GILDGilead Sciences, Inc.
1.33%73.320.9%$534.10m
CELGCelgene Corporation
0.35%91.201.2%$502.04m
AMGNAmgen Inc.
-0.13%197.311.2%$470.98m
ILMNIllumina, Inc.
1.67%331.443.5%$390.25m
REGNRegeneron Pharmaceuticals, Inc.
1.00%378.562.6%$309.76m
VRTXVertex Pharmaceuticals Incorporated
0.65%176.861.9%$202.70m
ALXNAlexion Pharmaceuticals, Inc.
0.71%116.992.0%$186.49m
AAgilent Technologies, Inc.
0.75%64.951.5%$163.20m
SRPTSarepta Therapeutics, Inc.
1.18%129.1416.6%$139.77m
NKTRNektar Therapeutics
2.24%61.965.6%$128.47m
EXASExact Sciences Corporation
1.71%50.0525.3%$122.85m
BLUEBluebird Bio, Inc.
0.06%158.8014.6%$120.19m
BMRNBioMarin Pharmaceutical Inc.
0.72%99.744.4%$119.07m
INCYIncyte Corporation
0.83%69.622.5%$116.18m

Company Profile

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company utilizing a novel technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its platform DNAbilize, uses P-ethoxy, which is a deoxyribonucleic acid backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a neutral charged lipid bilayer. The company was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Maria Tari on May 10, 2007 and is headquartered in Bellaire, TX.